DNMT3A and leukemia: As a consequence, presence of DNMT3A mutations in patients with no evidence of residual leukemia may be considered as persistent preleukemic clones rather than as leukemia (stem) cells, and their use as markers for molecular detection of minimal residual disease has been argued against [93,94].